Consistent with the data obtained from IL-17A systemic application, infection with CR/IL17 limited the body weight loss and the systemic bacterial dissemination consequent to IL-33 treatment (Supplementary Fig. 3b–d). The gene discussed is IL17A; the disease is infection.